Latest News

  • Alkermes to Host Conference Call to Discuss First Quarter 2021 Financial Results Read More
  • Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society Read More
  • Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer Read More
  • Alkermes to Take Part in Stifel's 3rd Annual CNS Day Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

COVID-19

Response to Current Events
COVID-19 Read Our Response